Psychedelic Research in
Kazakhstan
Kazakhstan appears to have a tightly controlled, largely medicalised environment for ketamine, with no clear evidence of routine public access to classical psychedelics for mental-health use. Available official material points to state registration and control of medicines, while a government document listing controlled substances includes ketamine among regulated substances and also shows several psychoactive compounds under control.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Kazakhstan.
- 1
The practical pathway in Kazakhstan is likely to be through regulated medical channels rather than any open-access or private psychedelic market.
- 2
The evidence located here supports control of psychoactive substances, but not a visible, mature psychedelic research cluster.
- 3
Ketamine is the most relevant compound for Blossom's current Kazakhstan footprint, but the available sources do not establish psychiatric routine use or local esketamine availability.
- 4
The public-source search did not identify active Kazakhstan psychedelic trials, which fits Blossom's linked count of one total trial and zero active linked trials.
- 5
Any near-term policy change would more likely come through medicines-registration or controlled-substances administration than through liberalisation of access.
Research Snapshot
Blossom currently tracks 1 psychedelic clinical trial connected to Kazakhstan.
- Active trials
- 0
- Total trials
- 1
- Stakeholders
- 0
- Events
- 0
None marked active
Country-linked records
No linked stakeholders
No linked events
Top Compounds
- Esketamine(1)
Top Study Topics
- Treatment-Resistant Depression (TRD)(1)
Medical Access Snapshot
Kazakhstan maintains a restrictive, control-focused approach to classical psychedelics and novel psychoactive compounds: most serotonergic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca) are listed in national controlled-substance schedules with no authorized general medical use outside approved research. Ketamine is registered and used in medical practice (primarily anaesthesia and acute analgesia) and is subject to strengthened controls; esketamine (Spravato) does not appear to be registered for routine clinical...
Regulatory Status
Kazakhstan's access environment appears restrictive: medicines require state registration for legal circulation, and controlled psychoactive substances are subject to national control. On the sources found here, ketamine is present in Kazakhstan's controlled/monitored medicines environment, but I did not find a reliable official source confirming routine psychiatric use or registration of esketamine for depression; treat those points as uncertain unless corroborated by a current national register entry.
Country Details
- Region
- Asia
- Last updated
- 18 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Kazakhstan maintains a restrictive, control-focused approach to classical psychedelics and novel psychoactive compounds: most serotonergic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca) are listed in national controlled-substance schedules with no authorized...
Open access guide →Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Kazakhstan.